source
- Ascletis pursues oral IL-17A inhibitor for psoriasis as Invivyd readies COVID-19 filingAscletis, a biotech listed in Hong Kong, is developing a small‑molecule IL-17A inhibitor in pill form to treat psoriasis. The company aims to challenge the current injectable therapies that target…
- Anthropic joins ARPA‑H clinical AI moonshot and will host a closed‑door health‑care eventAnthropic, an artificial‑intelligence firm, announced it is joining a new clinical‑AI initiative launched by the U.S. Biomedical Advanced Research Projects Agency‑Health (ARPA‑H). The partnership…